Baird has lowered its price target for Teradyne from $420 to $385 following the company's Q3 2026 earnings and Q4 guidance. This adjustment indicates a revised valuation perspective from the analyst firm, which could exert downward pressure on Teradyne's stock in the short term.
Baird has reduced its price target for Teradyne (TER) from $420 to $385. This action directly stems from Teradyne's recently reported third-quarter 2026 earnings and its subsequent fourth-quarter guidance, which likely led Baird to reassess the company's future prospects and valuation. This is significant for Teradyne investors as analyst price target adjustments can influence market sentiment and trading activity, potentially leading to short-term downward pressure on the stock. While not a direct operational change, it reflects an expert's revised outlook, which could impact investor confidence. The key risk for traders is potential short-term selling pressure as the market digests this revised valuation.